Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jan;55(1):433-5.
doi: 10.1128/AAC.00813-10. Epub 2010 Oct 11.

High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit

Carole Giraud  1 , Sandra Manceau, Mehdi Oualha, Hélène Chappuy, Agnès Mogenet, Patrick Duchêne, Sarah Ducrocq, Philippe Hubert, Jean M Treluyer
Affiliations

High levels and safety of oseltamivir carboxylate plasma concentrations after nasogastric administration in critically ill children in a pediatric intensive care unit

Carole Giraud et al. Antimicrob Agents Chemother. 2011 Jan.

Abstract

During the 2009 H1N1 influenza pandemics, the concentrations of oseltamivir (O) and its active metabolite (oseltamivir carboxylate [OC]) were determined in 11 children (1 month to 16 years of age) admitted to intensive care units for presumed severe H1N1 infection. They received oseltamivir phosphate (OP) nasogastrically at doses between 1.5 and 6.8 mg/kg of body weight. High OC concentrations were found, with a mean level of 678 ± 535 μg/liter. The mean OP concentration was 27 ± 52 μg/liter. No marked side effect was reported.

PubMed Disclaimer

References

    1. Abe, M., J. Smith, A. Urae, J. Barrett, H. Kinoshita, and C. R. Rayner. 2006. Pharmacokinetics of oseltamivir in young and very elderly subjects. Ann. Pharmacother. 40:1724-1730. - PubMed
    1. Acosta, E. P., P. Jester, P. Gal, J. Wimmer, J. Wade, R. J. Whitley, and D. W. Kimberlin. 2010. Oseltamivir dosing for influenza infection in premature neonates. J. Infect. Dis. 202:563-566. - PMC - PubMed
    1. Ariano, R. E., D. S. Sitar, S. A. Zelenitsky, R. Zarychanski, A. Pisipati, S. Ahern, S. Kanji, J. Rello, and A. Kumar. 2010. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 182:357-363. - PMC - PubMed
    1. Bantia, S., C. D. Parker, S. L. Ananth, L. L. Horn, K. Andries, P. Chand, P. L. Kotian, A. Dehghani, Y. El-Kattan, T. Lin, T. L. Hutchison, J. A. Montgomery, D. L. Kellog, and Y. S. Babu. 2001. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob. Agents Chemother. 45:1162-1167. - PMC - PubMed
    1. Brewster, M., J. R. Smith, R. Dutkowski, and R. Robson. 2006. Active metabolite from Tamiflu solution is bioequivalent to that from capsule delivery in healthy volunteers: a cross-over, randomised, open-label study. Vaccine 24:6660-6663. - PubMed

Publication types

MeSH terms

LinkOut - more resources